We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

3 hedge funds and large institutions have $11K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $10K → $11K (+$1K)

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
QCIG
Quad-Cities Investment Group
Iowa
+$1K

Top Sellers

Rank Fund Capital Flow
1
ACM
Academy Capital Management
Texas
-$1K
2
FWM
Focused Wealth Management
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$7K – – –
BO
2
BRR OpCo
Ohio
$3K – – –
QCIG
3
Quad-Cities Investment Group
Iowa
$1K +$1K +10,600 New
ACM
4
Academy Capital Management
Texas
– -$1K -20,000 Closed
FWM
5
Focused Wealth Management
New York
– -$1K -9,250 Closed

PVCT Hedge Fund Activity: Q2 2018 in Review

3 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2018, worth a combined $11K — up 10% from $10K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PVCT and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Quad-Cities Investment Group, opening a new position worth an estimated $1K. The largest seller was Academy Capital Management, exiting entirely with an estimated $1K sold.

  • 3 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2018, down from 4 in Q1 2018.
  • Funds reported $11K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2018, up 10% quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2018 and 2 closed out, a net change of -1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q2 2018 was Quad-Cities Investment Group, an estimated $1K added.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q2 2018 was Academy Capital Management, an estimated $1K sold.

Based on aggregated 13F filings for Q2 2018.